

GP 1816

PATENT  
Attorney Docket No. OPHD-02304

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: James A. Williams *et al.*

Serial No.: 08/704,159

Group No.: 1816

Filed: August 28, 1996

Examiner:

Entitled: **MULTIVALENT VACCINE FOR CLOSTRIDIUM  
BOTULINUM NEUROTOXIN**

SEP 18 1997  
GROUP 1800

INFORMATION DISCLOSURE  
STATEMENT TRANSMITTAL

Assistant Commissioner for Patents  
Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Dated: September 2, 1997

By:

Marilyn Moy  
Marilyn Moy

Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.


Dated: September 2, 1997

Virginia S. Medlen  
Virginia S. Medlen  
Registration No. 32,050

Please direct all correspondence to:

Peter G. Carroll  
Registration No. 32,837

MEDLEN & CARROLL, LLP  
220 Montgomery Street, Suite 2200  
San Francisco, California 94104  
415/705-8410



#6  
W/Burke  
9/22/97

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: James A. Williams *et al.*

Serial No.: 08/704,159

Group No.: 1816

Filed: August 28, 1996

Examiner:

Entitled: **MULTIVALENT VACCINE FOR  
CLOSTRIDIUM BOTULINUM NEUROTOXIN**

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

### CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231, on September 2, 1997.

By: Marilyn Moy

Marilyn Moy

Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

The following printed patent is referred to in the body of the specification:

- U.S. Patent No. 5,080,895, issued January 14, 1992, to Tokoro;

The following printed publications are referred to in the body of the specification:

- Cato *et al.* (1986) "Clostridium," in *Bergey's Manual® of Systematic Bacteriology*, 2:1141-1200, Sneath (ed.), Williams & Wilkins;
- Engelkirk *et al.* (1992) "Classification," in *Principles and Practice of Clinical Anaerobic Bacteriology*, pp. 22-23, Star Publishing Co., Belmont, CA;

- Stephen and Pietrowski (1986) "Toxins Which Traverse Membranes and Deregulate Cells," in *Bacterial Toxins*, 2d ed., pp. 66-67, American Society for Microbiology;
- Berkow and Fletcher (eds.) (1992) "Bacterial Diseases," in *Merck Manual of Diagnosis and Therapy*, 16th ed., pp. 116-126, Merck Research Laboratories, Rahway, N.J.;
- Sigmund and Fraser (eds.) (1979) "Clostridial Infections," in *Merck Veterinary Manual*, 5th ed., pp. 396-409, Merck & Co., Rahway, N.J.;
- Hatheway (1990) "Bacteriophages and plasmids and their roles in coding for botulinal neurotoxins," *Clin. Microbiol. Rev.* 3:73-74;
- Arnon (1986) "Infant Botulism: Anticipating the Second Decade," *J. Infect. Dis.* 154:201-206;
- Arnon (1980) "Infant Botulism," *Ann. Rev. Med.* 31:541-559;
- MacDonald *et al.* (1986) "The Changing Epidemiology of Adult Botulism in the United States," *Am. J. Epidemiol.* 124:794-799;
- Tacket *et al.* (1984) "Equine Antitoxin Use and Other Factors That Predict Outcome in Type A Foodborne Botulism," *Am. J. Med.* 76:794-798;
- Swartz (1990) "Anaerobic Spore-Forming Bacilli: The Clostridia," in *B.D. Microbiology*, 4th edition, pp. 633-646, Davis *et al.* (eds.), J.B. Lippincott Co.;
- Holzer (1962) "Botulismus durch Inhalation," *Med. Klin.* 41:1735-738;
- Franz *et al.* (1993) in *Botulinum and Tetanus Neurotoxins*, pp. 473-476, B.R. DasGupta, ed., Plenum Press, NY;
- Arnon *et al.* (1981) "Infant Botulism: Epidemiology and Relation to Sudden Infant Death Syndrome," *Epidemiol. Rev.* 3:45-66;
- Frankovich and Arnon (1991) "Clinical Trial of Botulism Immune Globulin for Infant Botulism," *West. J. Med.* 154:103;
- Sugiyama (1980) "*Clostridium botulinum* Neurotoxin," *Microbiol. Rev.* 44:419-448;
- Balady (1991) "Botulism Antitoxin Fielded for Operation Desert Storm," *USAMRDC Newsletter*, p. 6;

- Schwarz and Arnon (1992) "Botulism Immune Globulin for Infant Botulism Arrives-One Year and A Gulf War Later," *Western J. Med.* 156:197-198;
- Peterson *et al.* (1979) "The Sudden Infant Death Syndrome and Infant Botulism," *Rev. Infect. Dis.* 1:630-634;
- Arnon *et al.* (1978) "Intestinal Infection and Toxin Production by *Clostridium Botulinum* as One Cause of Sudden Infant Death Syndrome," *Lancet*, pp. 1273-1277;
- Informational Brochure for the Pentavalent (ABCDE) Botulinum Toxoid, Centers for Disease Control, Rev. 1995, pp. 1-3 and 3 unnumbered pages;
- Brooks *et al.* (eds.) (1991) "Infections Caused by Anaerobic Bacteria," in *Jawetz, Melnick, & Adelberg's Medical Microbiology*, 19th ed., pp. 257-262, Appleton & Lange, San Mateo, CA;
- Engelkirk *et al.* (1992) *Principles and Practice of Clinical Anaerobic Bacteriology*, pp. 64-67, Star Publishing Co., Belmont, CA;
- Lyerly *et al.* (1992) "Characterization of a Toxin A-Negative, Toxin B-Positive Strain of *Clostridium difficile*," *Infect. Immun.* 60:4633-4639;
- Borriello *et al.* (1990) "Virulence Factors of *Clostridium difficile*," *Rev. Infect. Dis.*, 12(Suppl. 2):S185-S191;
- Lyerly *et al.* (1985) "Effects of *Clostridium difficile* Toxins Given Intragastrically to Animals," *Infect. Immun.* 47:349-352;
- Rolfe (1990) "Binding Kinetics of *Clostridium difficile* Toxins A and B to Intestinal Brush Border Membranes from Infant and Adult Hamsters," *Infect. Immun.* 59:1223-1230;
- Kim and Rolfe (1987) "The Protective Role of Antibody to Toxin A in *Clostridium difficile* - Induced Ileocectitis," *Abstr. Ann. Meet. Am. Soc. Microbiol.* 69:62;
- Banno *et al.* (1984) "Biochemical Characterization and Biologic Actions of Two Toxins (D-1 and D-2) From *Clostridium difficile*," *Rev. Infect. Dis.* 6(Suppl. 1):S11-S20;
- Rihn *et al.* (1984) "A New Purification Procedure for *Clostridium difficile* Enterotoxin," *Biochem. Biophys. Res. Comm.* 124:690-695;

- Justus *et al.* (1982) "Myoelectric Effects of *Clostridium difficile*: Motility-Altering Factors Distinct From its Cytotoxin and Enterotoxin in Rabbits," *Gastroenterol.* 83:836-843
- Finegold *et al.* (1992) "Antimicrobial-Associated Pseudomembranous Colitis," in *Clinical Guide to Anaerobic Infections*, pp. 88-89, Star Publishing Co., Belmont, CA;
- United States Pharmacopeia (1990) United States Pharmacopeial Convention, Vol. XXII:1515-1516; Rockville, MD;
- FDA Guidelines for Parenteral Drugs (December 1987); *i.e.*, *Guideline on Validation of the Limulus Amebocyte Lysate Test as an End-Product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products and Medical Devices*;
- Pearson (1985) "Equivalency of LAL and USP Rabbit Pyrogen Tests," in *Pyrogens: endotoxins, lal testing and depyrogenation*, Marcel Dekker, NY, pp. 150-155;
- Minton (1995) "Molecular Genetics of Clostridial Neurotoxins," *Curr. Top. Microbiol. Immunol.* 195:161-194
- Benedict and Yamaga (1966) "Immunoglobulins and Antibody Production in Avian Species," in *Comparative Immunology*, pp. 335-375 (J.J. Marchaloni, ed.), Blackwell, Oxford;
- Patterson *et al.* (1962) "Antibody Production and Transfer to Egg Yolk in Chickens," *Immunol.* 89:272-278;
- Carroll and Stollar (1983) "Antibodies of Calf Thymus RNA Polymerase II from Egg Yolks of Immunized Hens," *J. Biol. Chem.* 258:24-26;
- Polson *et al.* (1980) "Antibodies to Proteins from Yolk of Immunized Hens," *Immunol. Comm.* 9:495-514;
- DasGupta and Sugiyama (1972) "A Common Subunit Structure In *Clostridium Botulinum* Type A, B, and E Toxins," *Biochem. Biophys. Res. Commun.* 48:108-112
- DasGupta (1990) "Structure and Biological Activity of Botulinum Neurotoxin," *J. Physiol.* 84:220-228;

- Halpern and Loftus (1993) "Characterization of the Receptor-binding Domain of Tetanus Toxin," J. Biol. Chem. 268:11188-11192;
- Whelan *et al.* (1992) "Molecular Cloning of the *Clostridium botulinum* Structural Gene Encoding the Type B Neurotoxin and Determination of Its Entire Nucleotide Sequence," Appl. Environ. Microbiol. 58:2345-2354;
- Sakaguchi (1983) "*Clostridium Botulinum* Toxins," Pharmac. Ther. 19:165-194;
- Moberg and H. Sugiyama (1978) "Affinity Chromatography Purification of Type A Botulinum Neurotoxin from Crystalline Toxic Complex," Appl. Environ. Microbiol. 35:878-880;
- Thalley *et al.* (1993) "Development of an Avian Antitoxin to Type A Botulinum Neurotoxin," in *Botulinum and Tetanus Neurotoxins*, pp. 467-472, B.R. DasGupta, ed., Plenum Press, NY;
- Schantz and Johnson (1992) "Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine," Microbiol. Rev. 56:80-99;
- Makoff *et al.* (1989) "Expression of Tetanus Toxin Fragment C in *E. Coli*: Its Purification and Potential Use as a Vaccine," Bio/Technology 7:1043-1046;
- Makoff *et al.* (1989) "Expression of tetanus toxin fragment C in *E. coli*: high level expression by removing rare codons," Nucl. Acids Res. 17:10191-10202
- Halpern *et al.* (1990) "Cloning and Expression of Functional Fragment C of Tetanus Toxin," Infect. Immun. 58:1004-1009;
- Romanos *et al.* (1991) "Expression of tetanus toxin fragment C in yeast: gene synthesis is required to eliminate fortuitous polyadenylation sites in AT-rich DNA," Nucleic Acids Res. 19:1461-1467;
- Charles *et al.* (1991) "Synthesis of Tetanus Toxin Fragment C in Insect Cells by Use of a Baculovirus Expression System," Infect. Immun. 59:1627-1632;
- Popoff *et al.* (1991) "Characterization of the C3 Gene of *Clostridium botulinum* Types C and D and Its Expression in *Escherichia coli*," Infect. Immun. 59:3673-3679;
- LaPenotiere *et al.* (1993) "Development of a Molecular Engineered Vaccine for *C. Botulinum* Neurotoxins," in *Botulinum and Tetanus Neurotoxins*, B.R. DasGupta, ed., Plenum Press, NY, pp. 463-466;

- Thompson *et al.* (1990) The complete amino acid sequence of the *Clostridium botulinum* type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene," Eur. J. Biochem. 189:73-81;
- LaPenotiere *et al.* (1995) "Expression of a Large, Nontoxic Fragment of Botulinum Neurotoxin Serotype A and Its Use as an Immunogen," Toxicon. 33:1383-1386;
- Middlebrook and Brown (1995) "Immunodiagnosis and Immunotherapy of Tetanus and Botulinum Neurotoxins," Curr. Top. Microbiol. Immunol. 195:89-122;
- Hutson *et al.* (1994) "Nucleotide Sequence of the Gene Coding for Non-Proteolytic *Clostridium botulinum* Type B Neurotoxin: Comparison with Other Clostridial Neurotoxins," Curr. Microbiol. 28:101-110;
- Poulet *et al.* (1992) "Sequences of the Botulinal Neurotoxin E Derived from *Clostridium Botulinum* Type E (Strain Beluga) and *Clostridium Butyricum* (Strains ATCC 43181 and ATCC 43755)," Biochem. Biophys. Res. Commun. 183:107-113;
- Whelan *et al.* (1992) "The complete amino acid sequence of the *Clostridium botulinum* type-E neurotoxin, derived by nucleotide-sequence analysis of the encoding gene," Eur. J. Biochem. 204:657-667;
- Fujii *et al.* (1993) "The complete nucleotide sequence of the gene encoding the nontoxic component of *Clostridium botulinum* type E progenitor toxin," J. Gen. Microbiol. 139:79-86;
- Delmee *et al.* (1990) "Characterization of Flagells of *Clostridium difficile* and Their Role in Serogrouping Reactions," J. Clin. Microbiol. 28:2210-2214;
- Delmee and Avesani (1990) "Virulence of ten serogroups of *Clostridium difficile* in hamsters," J. Med Microbiol. 33:85-90;
- Toma *et al.* (1988) "Serotyping of *Clostridium difficile*," J. Clin. Microbiol. 26:426-428;
- Delmee *et al.* (1985) "Serogrouping of *Clostridium difficile* Strains by Slide Agglutination," J. Clin. Microbiol. 21:323-327;

- Davies and Borriello (1990) "Detection of Capsule in Strains of *Clostridium difficile* of Varying Virulence and Toxigenicity," Microbial Path. 9:141-146;
- Edelstein (1990) "Processing Clinical Specimens for Anaerobic Bacteria: Isolation and Identification Procedures," in *Bailey and Scott's Diagnostic Microbiology*, pp. 477-507, C.V. Mosby Co.; Baron and Finegold (eds.);
- Padhye *et al.* (1990) "Production and Characterization of a Monoclonal Antibody Specific for Enterohemorrhagic *Escherichia coli* of Serotypes 0157:H7 and 026:H11," J. Clin. Microbiol. 29:99-103;
- Lyerly *et al.* (1991) "Passive Immunization of Hamsters Against Disease Caused by *Clostridium difficile* by Use of Bovine Immunoglobulin G Concentrate," Infect. Immun. 59:2215-2218;
- DasGupta & Sathyamoorthy (1984) "Purification and Amino Acid Composition of Type A Botulinum Neurotoxin," Toxicon, 22:415-424;
- Singh & DasGupta (1989) "Molecular Differences Between Type A Botulinum Neurotoxin and Its Toxoid," Toxicon 27:403-410;
- Towbin *et al.* (1979) "Electrophoretic Transfer of Proteins from Polyacrylamide Gels to Nitrocellulose Sheets: Procedure and Some Applications," Proc. Natl. Acad. Sci. USA, 76:4350-4354;
- Weber and Osborn (1975) "Proteins and Sodium Dodecyl Sulfate: Molecular Weight Determination on Polyacrylamide Gels and Related Procedures," in *The Proteins*, pp. 179-223, 3d Edition (H. Neurath & R.L. Hill, eds), Academic Press, NY;
- Carroll and Laughon (1987) "Production and purification of polyclonal antibodies to the foreign segment of  $\beta$ -galactosidase fusion proteins," in *DNA Cloning: A Practical Approach*, Vol.III, pp. 89-111, D. Glover (ed.) IRL Press, Oxford;
- Thalley and Carroll (1990) "Rattlesnake and Scorpion Antivenoms From The Egg Yolks of Immunized Hens," Bio/Technology 8:934-938;
- Ohishi *et al.* (1977) "Oral Toxicities of *Clostridium botulinum* Toxins in Response to Molecular Size," Infect. Immun. 16:106-107;



- Wren *et al.* (1991) "Antigenic Cross-Reactivity and Functional Inhibition by Antibodies to *Clostridium difficile* Toxin A, *Streptococcus mutans* Glucan-Binding Protein, and a Synthetic Peptide," *Infect. Immun.* 59:3151-3155;
- Ehrich *et al.* (1980) "Production of *Clostridium difficile* Antitoxin," *Infect. Immun.* 28:1041-1043;
- McGee *et al.* (1992) "Local induction of tumor necrosis factor as a molecular mechanism of mucosal damage by gonococci," *Microb. Path.* 12:333-341;
- Fekety (1986) "Animal Models of Antibiotic-Induced Colitis," in *Experimental Models in Antimicrobial Chemotherapy*, 2:61-72, Zak and Sande (eds.), Harcourt Brace Jovanovich, NY
- Borriello *et al.* (1987) "*Clostridium difficile*-a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis," *J. Med. Microbiol.* 24:53-64;
- Kim *et al.* (1987) "Immunization of Adult Hamsters Against *Clostridium difficile*-Associated Ileocectitis and Transfer of Protection to Infant Hamsters," *Infect. Immun.* 55:2984-2992;
- Borriello *et al.* (1988) "*Mucosal Association by Clostridium difficile* in the hamster gastrointestinal tract," *J. Med. Microbiol.* 25:191-196;
- Dove *et al.* (1990) "Molecular Characterization of the *Clostridium difficile* Toxin A Gene," *Infect. Immun.* 58:480-488;
- Williams *et al.* (1995) "Expression of foreign proteins in *E. coli* using plasmid vectors and purification of specific polyclonal antibodies," in *DNA Cloning 2: Expression Systems*, pp. 15-58, Glover and Hames (eds.) IRL Press, Oxford;
- von Eichel-Streiber and Sauerborn (1990) "*Clostridium difficile* Toxin A Carries a C-Terminal Repetitive Structure Homologous to the Carbohydrate Binding Region of Streptococcal Glycosyltransferases," *Gene* 96:107-113;
- Wren and Tabaqchali (1987) "Restriction Endonuclease DNA Analysis of *Clostridium difficile*," *J. Clin. Microbiol.* 25:2402-2404;
- Price *et al.* (1987) "Cloning of the Carbohydrate-binding Portion of the Toxin A Gene of *Clostridium difficile*," *Curr. Microbiol.* 16:55-60;

- Krivan *et al.* (1986) "Cell Surface Binding Site for *Clostridium difficile* Enterotoxin: Evidence for a Glycoconjugate Containing the Sequence Gal $\alpha$ 1-3Gal $\beta$ 1-4GlcNAc," *Infect. Immun.*, 53:573-581;
- von Eichel-Streiber *et al.* (1989) "Cloning and Characterization of Overlapping DNA Fragments of the Toxin A Gene of *Clostridium difficile*," *J. Gen. Microbiol.* 135:55-64;
- Lyerly *et al.* (1989) "Nonspecific Binding of Mouse Monoclonal Antibodies to *Clostridium difficile* Toxins A and B," *Curr. Microbiol.* 19:303-306;
- Lyerly *et al.* (1990) "Vaccination Against Lethal *Clostridium difficile* Enterocolitis with a Nontoxic Recombinant Peptide of Toxin A," *Curr. Microbiol.* 21:29-32;
- Swanson *et al.* (1991) "*In Vitro* and *In Vivo* Evaluation of Tiacumcins B and C Against *Clostridium difficile*," *Antimicro. Agents and Chemo.* 35:1108-1111
- Swanson *et al.* (1989) "Phenelfamycins, a Novel Complex of Elfamycin-type Antibiotics, III. Activity *In Vitro* and in a Hamster Colitis Model," *J. Antibiotics* 42:94-101;
- Barroso *et al.* (1990) "Nucleotide Sequence of *Clostridium difficile* Toxin B Gene," *Nucl. Acids Res.* 18:4004;
- Riggs (1989) in *Current Protocols in Molecular Biology*, Vol. 2, Ausubel, *et al.* (Eds.) pp. 16.6.1-16.6.14;
- von Eichel-Streiber *et al.* (1992) "Comparative Sequence Analysis of the *Clostridium difficile* Toxins A and B," *Molec. Gen. Genetics* 233:260-268;
- Thompson *et al.* (1990) "The complete amino acid sequence of the *Clostridium botulinum* type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene," *Eur. J. Biochem.* 189:73-81;
- Schantz and Kautter (1978) "Microbiological Methods: Standardized Assay for *Clostridium botulinum* Toxins," *J. AOAC* 61:96-99;
- Investigational New Drug (BB-IND-3703) application by the Surgeon General of the Department of the Army to the Federal Food and Drug Administration;
- Pearson (1985) *Pyrogens: endotoxins, LAL testing and depyrogenation*, Marcel Dekker, NY, pp. 23-56;

- Smith and Corcoran (1994) "Expression and Purification of Glutathione-S-Transferase Fusion Proteins," Current Protocols in Molecular Biology, Supplement 28:16.7.1-16.7.7;
- Gragerov *et al.* (1992) "Cooperation of GroEL/GroES and DnaK/DnaJ heat shock proteins in preventing protein misfolding in *Escherichia coli*," Proc. Natl. Acad. Sci. USA 89:10341-10344;
- Fujii *et al.* (1990) "The Nucleotide and Deduced Amino Acid Sequences of *EcoRI* Fragment Containing the 5'-Terminal Region of *Clostridium botulinum* Type E Toxin Gene Cloned from Mashike, Iwanai and Otaru Strains," Microbiol. Immunol. 34:1041-1047
- Kimura *et al.* (1990) "The Complete Nucleotide Sequence of the Gene Coding for Botulinum Type C<sub>1</sub> Toxin in the C-St Phage Genome," Biochem. Biophys. Res. Comm. 171:1304-1311;
- Sunagawa *et al.* (1992) "The Complete Amino Acid Sequence of the *Clostridium botulinum* Type D Neurotoxin, Deduced by Nucleotide Sequence Analysis of the Encoding Phage d-16φ Genome," J. Vet. Med. Sci. 54:905-913;
- Binz *et al.* (1990) "Nucleotide sequence of the gene encoding *Clostridium botulinum* neurotoxin type D," Nucleic Acids Res. 18:5556; and
- Campbell *et al.* (1993) "Nucleotide sequence of the gene coding for *Clostridium botulinum* (*Clostridium argentinense*) type G neurotoxin: genealogical comparison with other clostridial neurotoxins," Biochim. Biophys. Acta 1216:487-491.

Applicants have become aware of the following printed publications which may be material to the examination of this application:

- East *et al.* (1992) "Sequence of the gene encoding type F neurotoxin of *Clostridium botulinum*," FEMS Micro. Letters 96:225-230. East *et al.* describes the cloning strategy and sequence determination of *Clostridium botulinum* type F toxin gene, and discloses the nucleotide sequence of that gene. However, East *et al.* does not disclose (a) host cells containing a recombinant expression vector which encodes at least a portion of *Clostridium botulinum* type B or type E toxin, (b) host cells which express a fusion protein comprising a non-toxin

portion and at least a portion of *Clostridium botulinum* type B or type E toxin, (c) vaccines comprising such fusion proteins, or (d) methods of generating antibodies using such fusion proteins;

- Niemann (1992) "Clostridial Neurotoxins - Proposal of a Common Nomenclature," Toxicon 30:223-225. Niemann proposes a common nomenclature for the neurotoxins of *Clostridium tetanus* and *Clostridium botulinum*. However, Niemann does not disclose (a) host cells containing a recombinant expression vector which encodes at least a portion of *Clostridium botulinum* type B or type E toxin, (b) host cells which express a fusion protein comprising a non-toxin portion and at least a portion of *Clostridium botulinum* type B or type E toxin, (c) vaccines comprising such fusion proteins, or (d) methods of generating antibodies using such fusion proteins;
- Food and Drug Administration Document (Docket No. 79D-0465) 53 FR 5044, February 19, 1988. The Food and Drug Administration announced in this document the availability of a guideline for the use of the Limulus Amebocyte Lysate (LAL) test as an end-product endotoxin test for human injectable drugs (including biological products), animal injectable drugs, and medical devices. By following the procedures set forth in the guideline, manufacturers of the above mentioned products may use the LAL test as an alternative to the official rabbit pyrogen test. In contrast to the claimed invention, this document does not discuss (a) host cells containing a recombinant expression vector which encodes at least a portion of *Clostridium botulinum* type B or type E toxin, (b) host cells which express a fusion protein comprising a non-toxin portion and at least a portion of *Clostridium botulinum* type B or type E toxin, (c) vaccines comprising such fusion proteins, or (d) methods of generating antibodies using such fusion proteins;
- Food and Drug Administration Document (Docket No. 79D-0465) 48 FR 27835, June 17, 1983. In this document, the Food and Drug Administration decided to extend the comment period for the notice announcing the availability of a draft guideline. The guideline was drafted for validation of the LAL test as an end-product endotoxin test for human and animal parenteral drugs,

biological products, and medical devices. Unlike the claimed invention, this document does not disclose (a) host cells containing a recombinant expression vector which encodes at least a portion of *Clostridium botulinum* type B or type E toxin, (b) host cells which express a fusion protein comprising a non-toxin portion and at least a portion of *Clostridium botulinum* type B or type E toxin, (c) vaccines comprising such fusion proteins, or (d) methods of generating antibodies using such fusion proteins; and

- Food and Drug Administration Document (Docket No. 79D-0465) 48 FR 13096, March 29, 1983. The Food and Drug Administration announced in this document the availability of a draft guideline for use of the LAL test as an end-product endotoxin test for human, biological, and animal injectable drugs and medical devices. However, this document does not disclose (a) host cells containing a recombinant expression vector which encodes at least a portion of *Clostridium botulinum* type B or type E toxin, (b) host cells which express a fusion protein comprising a non-toxin portion and at least a portion of *Clostridium botulinum* type B or type E toxin, (c) vaccines comprising such fusion proteins, or (d) methods of generating antibodies using such fusion proteins.

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: September 2, 1997



Virginia S. Medlen  
Registration No. 32,050

MEDLEN & CARROLL, LLP  
220 Montgomery Street, Suite 2200  
San Francisco, California 94104  
415/705-8410